Caitriona Cahir1, Stephan U Dombrowski2, Catherine M Kelly3, M John Kennedy4, Kathleen Bennett5, Linda Sharp6. 1. Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin, Ireland. cacahir@tcd.ie. 2. Division of Psychology, University of Stirling, Stirling, Scotland. 3. Medical Oncology, Mater University Hospital, Ireland and University College Dublin, Dublin, Ireland. 4. Medical Oncology, St James's Hospital, Ireland and Trinity College Dublin, Dublin, Ireland. 5. Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin, Ireland. 6. National Cancer Registry Ireland, Cork, Ireland.
Abstract
PURPOSE: Five to 10 years of adjuvant hormonal therapy is recommended to prevent breast cancer recurrence. This study investigated modifiable influences on adjuvant hormonal therapy medication-taking behaviour (MTB) in women with stage I-III breast cancer. METHODS: Semi-structured face-to-face interviews among women with stage I-III breast cancer prescribed adjuvant hormonal therapy purposively sampled by their MTB at two cancer centres. Thematic analysis was conducted based on the Framework approach, with the Theoretical Domains Framework (TDF) informing the analysis framework; the TDF is an integrative framework consisting of 14 domains of behavioural change to inform intervention design. RESULTS: Thirty-one women participated in interviews (14 adherent/persistent; 7 non-adherent/persistent; 10 non-persistent). Three domains identified both barriers and enablers to hormonal therapy MTB across the three MTB strata: beliefs about consequences, intentions and goals and behaviour regulation, but their influence was different across the strata. Other domains influenced individual MTB strata. Key enablers for adherent/persistent women were identified within the domain beliefs about consequences (breast cancer recurrence), intentions and goals (high-priority), beliefs about capabilities (side effects) and behaviour regulation (managing medication). Barriers were identified within the domain behaviour regulation (no routine), memory, attention and decision processes (forgetting) and environmental context and resources (stressors) for non-adherent/persistent women and intentions and goals (quality of life), behaviour regulation (temporal self-regulation), reinforcement, beliefs about consequences (non-necessity) and social influences (clinical support) for non-persistent women. CONCLUSION: This study identified modifiable influences on hormonal therapy MTB. Targeting these influences in clinical practice may improve MTB and hence survival in this population.
PURPOSE: Five to 10 years of adjuvant hormonal therapy is recommended to prevent breast cancer recurrence. This study investigated modifiable influences on adjuvant hormonal therapy medication-taking behaviour (MTB) in women with stage I-III breast cancer. METHODS: Semi-structured face-to-face interviews among women with stage I-III breast cancer prescribed adjuvant hormonal therapy purposively sampled by their MTB at two cancer centres. Thematic analysis was conducted based on the Framework approach, with the Theoretical Domains Framework (TDF) informing the analysis framework; the TDF is an integrative framework consisting of 14 domains of behavioural change to inform intervention design. RESULTS: Thirty-one women participated in interviews (14 adherent/persistent; 7 non-adherent/persistent; 10 non-persistent). Three domains identified both barriers and enablers to hormonal therapy MTB across the three MTB strata: beliefs about consequences, intentions and goals and behaviour regulation, but their influence was different across the strata. Other domains influenced individual MTB strata. Key enablers for adherent/persistent women were identified within the domain beliefs about consequences (breast cancer recurrence), intentions and goals (high-priority), beliefs about capabilities (side effects) and behaviour regulation (managing medication). Barriers were identified within the domain behaviour regulation (no routine), memory, attention and decision processes (forgetting) and environmental context and resources (stressors) for non-adherent/persistent women and intentions and goals (quality of life), behaviour regulation (temporal self-regulation), reinforcement, beliefs about consequences (non-necessity) and social influences (clinical support) for non-persistent women. CONCLUSION: This study identified modifiable influences on hormonal therapy MTB. Targeting these influences in clinical practice may improve MTB and hence survival in this population.
Entities:
Keywords:
Adherence; Breast cancer; Hormonal therapy; Medication-taking behaviour
Authors: Christopher R Friese; T May Pini; Yun Li; Paul H Abrahamse; John J Graff; Ann S Hamilton; Reshma Jagsi; Nancy K Janz; Sarah T Hawley; Steven J Katz; Jennifer J Griggs Journal: Breast Cancer Res Treat Date: 2013-03-31 Impact factor: 4.872
Authors: Aliza K Fink; Jerry Gurwitz; William Rakowski; Edward Guadagnoli; Rebecca A Silliman Journal: J Clin Oncol Date: 2004-08-15 Impact factor: 44.544
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: Lisa A McSherry; Stephan U Dombrowski; Jill J Francis; Judith Murphy; Cara M Martin; John J O'Leary; Linda Sharp Journal: Implement Sci Date: 2012-08-03 Impact factor: 7.327
Authors: Ekim Ekinci; Salima Nathoo; Thushara Korattyil; Aisha Vadhariya; Hanna A Zaghloul; Polly A Niravath; Susan M Abughosh; Meghana V Trivedi Journal: J Cancer Surviv Date: 2018-02-02 Impact factor: 4.442
Authors: Jo Brett; Mary Boulton; Debbie Fenlon; Nick J Hulbert-Williams; Fiona M Walter; Peter Donnelly; Bernadette A Lavery; Adrienne Morgan; Carolyn Morris; Eila K Watson Journal: Patient Prefer Adherence Date: 2018-02-16 Impact factor: 2.711
Authors: Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell Journal: Curr Oncol Date: 2021-07-05 Impact factor: 3.677
Authors: Jeff Ching-Fu Hsieh; Susanna M Cramb; James M McGree; Nathan A M Dunn; Peter D Baade; Kerrie L Mengersen Journal: BMC Public Health Date: 2015-12-02 Impact factor: 3.295
Authors: Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard; Stephen K Chia; Carolyn C Gotay Journal: BMC Cancer Date: 2018-07-11 Impact factor: 4.430